Granulocyte‐colony stimulating factor in <scp>COVID</scp>‐19: Is it stimulating more than just the bone marrow?
Authors: Tamara Nawar, Sejal Morjaria, Anna Kaltsas, Dhruvkumar Patel, Rocio Perez‐Johnston, Anthony F. Daniyan, Sham Mailankody, Rekha Parameswaran
Journal: American Journal of Hematology (2020)

To the Editor:Granulocyte-colony stimulating factor (GCSF) is routinely administered in cancer patients as prophylaxis or treatment of neutropenia. Although the safety profile of GCSF use in patients with symptomatic COVID-19 disease is unclear, lung findings from autopsies of patients showed neutrophil extravasation in the alveolar space.1 It is known that severe cases of COVID-19 have been reported to have a higher absolute neutrophil count (ANC)-absolute lymphocyte count (ALC) ratio2; both reported findings raise questions about the appropriate timing of administering growth factors to neutropenic patients with SARS-CoV-2 infection. Although clear causal evidence of GCSF administration leading to worse outcomes in COVID-19 patients does not yet exist, there are concerns regarding the potential for increased pulmonary inflammation and macrophage activation with GCSF use in this setting.3 Currently, there are no standardized treatments or medications available to treat COVID-19, so it is crucial to identify factors such as GCSF that may lead to a more severe outcome in COVID-19 patients. Herein, we describe three patients who received GCSF and developed severe disease from COVID-19 within 72 hours of administration. All patients were admitted to the hospital in late March 2020 for symptomatic COVID-19 infection, proven by qualitative RNA PCR assay. All three patients had a severe infection with SARS-CoV-2 and received hydroxychloroquine 400 mg twice a day for the first day, followed by 200 mg twice a day for four days, for a total five day course in accordance with hospital criteria that were in place at that time. Patient 1: A 65-year-old male with relapsed acute myeloid leukemia, on a regimen of azacitidine and venetoclax, with last dose one month prior to admission, had persistent neutropenia of one month duration prior to his admission for fever of 38.7oC and neutropenia. The ANC was 0.3 K/mcl and pulse oximetry was 99% on room air. Chest X-ray performed on the day of admission (hospital day 0) showed diffuse bilateral patchy lung opacities (Supplementary Figure 1). Upon hospital admission, he was empirically treated with aztreonam and vancomycin and received 480 mcg of filgrastim (GCSF) subcutaneously (SC) for neutropenia. On hospital day 2 (twenty-four hours after his dose of GCSF), the patient had worsening oxygen requirements necessitating intubation and transfer to the intensive care unit (ICU). Repeat chest X-ray showed increased bilateral lung opacities (Supplementary Figure 1). Laboratory workup revealed an increase in ANC to 2.2K/mcL (Table 1). GCSF total dose Dose day (480microgram vial) 4.8microgram/kg Admission day 7.8microgram/kg One dose each on days 5 + 8 3.9microgram/kg One dose each on days 1 + 2 Hydroxychloroquine Aztreonam Vancomycin Hydroxychloroquine Cefepime Clinical Course Day +1 Day +2 Day +3 Increasing hypoxia Intubation Shock, increasing hypoxia (Post dose 2) Shortness of breath Hypoxia: 78% room air Hypotension, no intubation (Post dose 2) Tachypnea 2L oxygen Worsening hypoxia Day +5 intubation On day 3 of hospitalization, he developed new atrial fibrillation and increasing vasopressor requirements. His ANC rose to 4.3K/mcL with rapidly rising ANC/ALC ratio. His hospital course was further complicated by recalcitrant shock, metabolic acidosis, and rising oxygen requirements. Discussion of goals of care with the family led to his terminal extubation. The patient expired on hospital day 12; on the day of death, the ANC/ALC ratio reached a maximum value of 11. Patient 2: A 35-year-old female, had mediastinal diffuse large B-cell lymphoma who underwent autologous stem cell transplant in January 2020, was admitted for fever and dry cough. Upon admission, she was hemodynamically stable except for a fever of 38.1oC. Her oxygen saturation was 99% on room air. Workup on admission revealed a normal chest X-ray and ANC of 4.1 K/mcL. During the first 2 days of hospitalization, the patient remained febrile, but otherwise hemodynamically stable and without an oxygen requirement. On hospital day 3, she developed worsening leukopenia with nadir ANC of 0.6 K/mcl. She remained febrile and was treated with piperacillin-tazobactam empirically for fever and neutropenia. Chest X-ray on day 3 revealed bilateral patchy lung opacities. On hospital day 5, she received a dose of GCSF 480 mcg SC and her ANC increased to 10.7 K/mcl 2 days later. The ANC decreased again to 0.6 K/mcl on day 12 of hospitalization for which she received a second dose of GCSF 480 mcg SC; the following day her ANC increased to 20.2 K/mcl. On day 14 (forty-eight hours after her second dose of GCSF), the patient developed increasing shortness of breath with rapid oxygen desaturation (nadir 78% on room air) requiring oxygen supplementation via a non-rebreather mask at 15 L/min. She had a rapidly rising ANC/ALC ratio in relation to clinical decline with maximal value of 22.63. Her chest CT revealed increased bilateral opacities at which time she also developed hypotension and tachycardia. Her oxygen requirements increased necessitating high flow oxygen. She slowly improved and was discharged on day 33 of hospitalization with a lower ANC/ALC ratio. Patient 3: A 58-year-old woman with invasive ductal carcinoma of the breast on doxorubicin and cyclophosphamide (last dose 10 days prior to admission) was admitted with fever and neutropenia (ANC on admission 0.6K/mcl). On admission, she was febrile to 39.2oC She was hemodynamically stable with an oxygen saturation of 99% on room air. She denied cough, chest pain or shortness of breath on admission. She was treated with cefepime at 2 g every 8 hours for neutropenic fever. Chest X-ray revealed faint bilateral opacities. She received GCSF at 480 mcg SC on the day of her admission. On day 2 of hospitalization, her ANC increased to 7.5 K/mcl but she still received a second dose of GCSF 480 mcg SC on this day. On hospital day 3, she became increasingly tachypneic (respiratory rate 30 breaths/minute) and was placed on 2 L oxygen by nasal cannula. Her laboratory workup revealed an elevation in her ANC to 16.5 K/mcl (hospitalization day 3) with a peak ANC/ALC ratio of 75. Repeat chest X-ray demonstrated worsening bilateral multifocal opacities. On day 5 of hospitalization, she was transferred to the ICU for worsening respiratory distress and was intubated on the same day. On hospital day 7, she developed acute respiratory distress syndrome and multiple organ failure and remained intubated for twenty days. Chest X-ray on day 13 revealed worsening lung findings. She was extubated on hospital day 25, and currently remains hospitalized but in stable condition. Later in her hospital course, she was noted to have a progressive decrease in the ANC/ALC ratio, correlating with clinical improvement in her respiratory symptoms. Data regarding outcomes in cancer patients with COVID-19 infection across the world are evolving. Febrile neutropenia is a major risk factor for infection related morbidity in cancer patients. Increased morbidity and mortality have been described in COVID patients with cancer as well as in those with comorbid medical conditions.4 To our knowledge, this is the first report describing the course of COVID-19 infection in selected cancer patients who received GCSF for neutropenic fever in the United States. All three patients developed a rising NLR >3 at 24 hours after GCSF administration. At 72 hours after administration of GCSF, all three patients had NLR >5 and suffered respiratory decline. The increase in ratio correlated with clinical decompensation as defined by worsening respiratory failure (Supplementary Figure 2). Of these, two patients with age >50 years and comorbid medical conditions developed decline severe enough to require mechanical ventilation. These two patients also had high IL 6 levels. Although increasingly described, the genesis of the cytokine release state in COVID-19 remains poorly understood. Data from China has shown that in patients over age 49.5 years and with ANC/ALC ratio >3.3, 46.1% of COVID-19 patients with mild disease will develop severe disease and that the mean time to such development is 6.3 days.5 This case series draws attention to the fact that GCSF can cause rapidly rising NLR ratio >3 within 24 hours of administration. In the setting of COVID-19 illness, further rapid rise in neutrophilia with NLR ratio >5 may portend respiratory deterioration to the point of mechanical ventilation within the next 72 hours, especially in those patients who are older than age 50 and have comorbid medical conditions. Limitations exist in our case series. This represents only a small number of patients who specifically came to our attention because they declined within 72 hours after receiving GCSF. Another limitation is missing data points regarding pre GCSF IL6 and other such markers, as these laboratory investigations were not performed on patients who initially had normal oxygenation on room air at admission. Larger scale studies are needed to delineate the relationship between GCSF administration and progression of COVID-19 infection from mild to severe stage in high risk patients. Figure S1 A i: Portable chest X-ray performed the day of GCSF administration demonstrating right basilar and left mid lung patch opacities. A ii: A day after the administration the airspace opacities increased bilaterally. B i: Portable chest X-ray performed two days prior to administration of GCSF demonstrating bilateral predominantly bibasilar patchy opacities. B ii and B iii: Axial and coronal images two days post GCSF administration, demonstrating peripheral and peribronchovascular airspace opacities predominantly in the lower lobes. C i: Portable X-ray at day 0 of GCSF administration demonstrating faint right basilar opacity. C ii: day 4 post GCSF administration, bilateral patch opacities noted involving both upper and lower zones. C iii: Day 13 post administration, increased bilateral diffuse reticular and airspace opacities Figure S2 Change in Absolute Neutrophil/Lymphocyte ratio ('ANC/ALC Ratio'; y-axis) over time ('Days'; x-axis). Day 0 corresponds to first G-CSF administration. As noted in the three graphs, the increase in ratio correlates with clinical decompensation as defined by worsening respiratory failure. A , The ANC/ALC ratio in relation to clinical decline in patient 1. At time of death, ANC/ALC reached a maximal value of 11. B, The ANC/ALC ratio in relation to clinical decline, reaching a maximal level of 22.63 followed by symptomatic improvement when the ANC/ALC ratio decreased in patient 2. C, Peak ANC/ALC ratio of 75, 1 day after G-CSF administration with progressive decrease in the ratio correlating with clinical improvement in respiratory symptoms Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.